Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH)
A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)
Sponsor: Bayer
Listed as NCT00901901, this PHASE3 trial focuses on Carcinoma, Hepatocellular and remains completed. Sponsored by Bayer, it has been updated 12 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2018 — Jun 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athens, Greece , Atlanta, United States , Auckland, New Zealand , Baltimore, United States , Barcelona, Spain , Barnaul, Russia , Beersheba, Israel , Beijing, China , Belo Horizonte, Brazil , Berlin, Germany and 104 more locations